RP-HPLC raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-05-14 and is reviewed periodically as new material appears.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
== Research == Oral administration of LGD-4033 to cynomolgus monkeys at daily doses varying from 0 to 75 mg/kg over 13 weeks demonstrated significant body weight gain in both males and females. After 48 days, the 75 mg/kg dose testing was halted due to toxicity concerns, but this did not negatively impact development of the drug as this dose is significantly higher than the doses being utilized in a phase 2 clinical trial. Two phase 1 clinical trials of LGD-4033 have been conducted and reported. The first was a single-dose study published as a conference abstract in 2010 and the second was a multi-dose study published as a journal article in 2013. The multi-dose phase 1 trial published in 2013 reported that LGD-4033 dose-dependently improved lean body mass and muscle strength in 76 healthy young men over 21 days. It was generally well-tolerated in this study, with no significant adverse effects reported. A phase 2 clinical trial, initiated on 3 November 2016, consisted of 108 women and men recovering from hip fracture surgery. The randomized study participants received either placebo or varying doses of LGD-4033 over a period of 12 weeks, with improved lean body mass as the primary endpoint. Other endpoints included satisfactory results in terms of quality of life, safety, and pharmacokinetics. This study was completed and results reported in 2017 and 2018. In the trial, LGD-4033 dose-dependently improved lean body mass and muscle strength and was reported to be safe and well-tolerated.
=== Urinary preparations === Purified urinary FSH (75 IU FSH and ≤ 2 IU of LH) Generic urofollitropin for injection, purified. Brands Bravelle, U.S., (≤ 2 IU LH) Metrodin, U.S. and Canada, (≤ 1 IU LH) Fertinorm Hp, (Canada) Highly purified urinary FSH (75 IU FSH and ≤ 0.1 IU LH/1000 IU FSH) Generic urofollitropin for injection, (highly) purified. Brands Fertinex (≤ 0.1 IU LH/1000 IU FSH)
glycoside Any chemical compound consisting of a carbohydrate molecule covalently bonded to another molecule containing a hydroxyl group (including other carbohydrates) via one or more C–O glycosidic bonds. When all of the compound's substituents are carbohydrates, the glycoside is a polysaccharide.
=== Depletion of adenine nucleotides === Having eliminated loss of respiration, Albrich et al. proposes that the cause of death may be due to metabolic dysfunction caused by depletion of adenine nucleotides. Barrette et al. studied the loss of adenine nucleotides by studying the energy charge of HClO-exposed cells and found that cells exposed to HClO were unable to step up their energy charge after addition of nutrients. The conclusion was that exposed cells have lost the ability to regulate their adenylate pool, based on the fact that metabolite uptake was only 45% deficient after exposure to HClO and the observation that HClO causes intracellular ATP hydrolysis. It was also confirmed that, at bacteriocidal levels of HClO, cytosolic components are unaffected. So it was proposed that modification of some membrane-bound protein results in extensive ATP hydrolysis, and this, coupled with the cells inability to remove AMP from the cytosol, depresses metabolic function. One protein involved in loss of ability to regenerate ATP has been found to be ATP synthetase. Much of this research on respiration reconfirms the observation that relevant bacteriocidal reactions take place at the cell membrane.
== Derivation == The Hagen–Poiseuille equation can be derived from the Navier–Stokes equations. The laminar flow through a pipe of uniform (circular) cross-section is known as Hagen–Poiseuille flow. The equations governing the Hagen–Poiseuille flow can be derived directly from the Navier–Stokes momentum equations in 3D cylindrical coordinates (r,θ,x) by making the following set of assumptions:
Sources: en.wikipedia.org
===== Other delivery methods: substance delivery in medical use ===== Near-infrared light: Drug release is triggered from heat. The infrared technology can be absorbed deep in the body, turn to heat. The heat-sensitive material, particularly a polymer shell that swells upon heating, collapses. The action of deflating is what releases the drug. Magnetic fields: Magnetic bars of millimeter-scale are embedded in poly(vinyl alcohol). The magnetic field within the bars is alternated, which results in the change of shape and ultimate collapse of the nanocapsules. The change in the structure then triggers the drug release. Ultrasound: Another option of drug release is through ultrasound, which is a "longitudinal pressure wave". The ultrasound can either be low-frequency, or LFUS, (between ~20 and ~100 kHz) or high-frequency, HFUS, (>1 MHz). Transdermal delivery (sonophoresis) is enhanced through LFUS, which then further allows the drug to be released. Since the wave of HFUS is higher, success of drug delivery has been demonstrated through the form of bubbles. The bubbles with in the capsule are formed and collapsed due to the higher temperatures of the wave. Some other ways include oral, which is the most active, nasal, transdermal, and through the lung. Oral is the most common, and the most challenging. Demands for consistent release persist, although developments are being made for drugs to bioadhere to the intestinal tract. Bioadhesion is also being considered for nasal delivery, to prolong the life of the drug within the nose.
Dose dumping is a phenomenon of drug metabolism in which environmental factors can cause the premature and exaggerated release of a drug. This can greatly increase the concentration of a drug in the body and thereby produce adverse effects or even drug-induced toxicity. Dose dumping is most commonly seen in drugs taken by mouth and digested in the gastrointestinal tract. Around the same time patients take their medication, they can also ingest other substances like fatty meals or alcohol that increase drug delivery. The substances may act on the drug's capsule to speed up drug release, or they may stimulate the body's absorptive surfaces to increase the rate of drug uptake. Dose dumping is a disadvantage found in extended release dosage form. In general, drug companies try to avoid drugs with significant dose dumping effects. Such drugs are prone to problems and are often pulled from the market. Such was the case with the pain medication Palladone Once Daily formulation due to its dose-dumping effects when taken with alcohol.
==== Soil preparation ==== In tropical cultivation, soil erosion is a major problem, requiring soil treatment to be as shallow as possible. Plowing is required only for high planting densities. In low planting densities, digging pits and refilling them with soil is preferable to ensure good root system penetration without causing too much land erosion. Optimal pits are 30–50 cm (12–20 in) deep and 20–40 cm (8–15+1⁄2 in) wide.
== Applications == Ion exchange is widely used in the food and beverage industry, hydrometallurgy, metals finishing, chemical, petrochemical, pharmaceutical technology, sugar and sweetener production, ground- and potable-water treatment, nuclear, softening, industrial water treatment, semiconductor, power, and many other industries. A typical example of application is preparation of high-purity water for power engineering, electronic and nuclear industries; i.e. polymeric or inorganic insoluble ion exchangers are widely used for water softening, water purification, water decontamination, etc. Ion exchange is a method widely used in household filters to produce soft water for the benefit of laundry detergents, soaps, and water heaters. This is accomplished by exchanging divalent cations (such as calcium Ca2+ and magnesium Mg2+) with highly soluble monovalent cations (e.g., Na+ or H+) (see water softening). Another application for ion exchange in domestic water treatment is the removal of nitrate and natural organic matter. In domestic filtration systems ion exchange is one of the alternatives for water softening in households along with reverse osmosis (RO) membranes. Compared to RO membranes, ion exchange requires repetitive regeneration when inlet water is hard (has high mineral content). Industrial and analytical ion-exchange chromatography is another area to be mentioned. Ion-exchange chromatography is a chromatographical method that is widely used for chemical analysis and separation of ions.
For services to the community in Rugby, Warwickshire. Margaret Sandra Myers. For services to the community in Sheffield, South Yorkshire. David Mynott. Volunteer, Torfaen Dementia Group. For services to People with Dementia and their Carers. Moez Kass Amali Nathu. Chief Executive, Peterborough Asylum and Refugee Community Association. For services to Refugees and Asylum Seekers in Peterborough. Robert Thomson Nellies. President, Falkland Cricket Club. For services to Cricket and to the community in Fife. Elyn Catherine Neville. For charitable services to Cancer Patients and to Cancer Services in Pembrokeshire. Margaret Alice Newell. Lately Office Manager, Privy Council Office. For Public Service, particularly during the Accession Council. Matthanee Nilavongse. For services to the community in Todmorden, West Yorkshire. William Ellis Nixon. Honorary Secretary, Social Enterprise UK. For services to Young People in the West Midlands. Uzoamaka Louisa Nwokolo. Lately Executive Officer, Department for Transport. For services to Young People. Diana Violet O'Grady. For services to the community in Arreton, Isle of Wight. Samuel Jozef Oldroyd. Chief Executive Officer, JADE Youth and Community. For services to Young People and Families in Rother Valley, South Yorkshire. Clive John Owen. Vice Chair, Aberavon Green Stars Rugby Football Club. For charitable services to Young People and to the community in Aberavon, West Glamorgan. Diane Oxley. For services to Young People and to the community in Thurcroft, South Yorkshire. Tracie Ann Pal.
Sources: en.wikipedia.org
== Background == As the second largest class of enzymes behind ubiquitin ligases and responsible for ~2% of any organism's genes, proteases have drawn the attention of biologists to develop a field aimed at identifying and quantifying their roles in biology. First coined in 2000 by the Overall Lab in McQuibban et al., degradomics was described as linking proteases to substrates on a proteome basis. The discoveries of novel roles for proteases and breakthroughs in protease-substrate discovery would be summarized later by Dr. Carlos Lopez-Otin and Dr. Chris Overall, introducing degradomics on a system-wide scale. They collated the current and emerging techniques available to describe proteolysis. By drawing attention to how proteolysis serves as an additional irreversible mechanism by which cells could achieve control over biological processes, they outlined the necessity of studying proteases for their functional relevance in processing bioactive molecules. These bioactive molecules play roles in coagulation, complement activation, DNA replication, cell-cycle control, cellular proliferation and migration, hemostasis, immunity, and apoptosis. The degradome was broken down into two concepts, the first referring the entire profile of proteases expressed under by a cell, tissue, or organism under defined circumstances. The second definition applies specifically to the full substrate repertoire of a certain protease in a cell, tissue, or organism. Dr. Overall's group would go on to annotate the complete human and mouse protease-inhibitor degradomes in 2003.
to represent these factors but it indeed is referenced to the initial stage when no action is taken to prevent the spread and all population is susceptible, thus all changes are absorbed by the change of
In 2004, a special issue of The International Journal of Sociology and Social Policy was published that was edited by Steven P. Schacht, who participated in the SSSP session. The special issue contained ten articles analyzing his research and his multiple contributions as a social activist and scholar. The authors of these articles call for sociologists and others to move beyond criticism of Humphrey's research methodologies in the tearoom study, and instead to focus on his pioneering contributions to the study of sexuality, participant-observation as method, development of sociological theory, and his work as a social activist and advocate for marginalized sexual identities.
John Lilley states, "...neutron-induced fission generates extra neutrons which can induce further fissions in the next generation and so on in a chain reaction. The chain reaction is characterized by the neutron multiplication factor k, which is defined as the ratio of the number of neutrons in one generation to the number in the preceding generation. If, in a reactor, k is less than unity, the reactor is subcritical, the number of neutrons decreases and the chain reaction dies out. If k > 1, the reactor is supercritical and the chain reaction diverges. This is the situation in a fission bomb where growth is at an explosive rate. If k is exactly unity, the reactions proceed at a steady rate and the reactor is said to be critical. It is possible to achieve criticality in a reactor using natural uranium as fuel, provided that the neutrons have been efficiently moderated to thermal energies." Moderators include light water, heavy water, and graphite. According to John C. Lee, "For all nuclear reactors in operation and those under development, the nuclear fuel cycle is based on one of three fissile materials, 235U, 233U, and 239Pu, and the associated isotopic chains. For the current generation of LWRs, the enriched U contains 2.5~4.5 wt% of 235U, which is fabricated into UO2 fuel rods and loaded into fuel assemblies." Lee states, "One important comparison for the three major fissile nuclides, 235U, 233U, and 239Pu, is their breeding potential.
=== Genomics and proteomics === At Caltech, Hood and his colleagues created the technological foundation for the study of genomics and proteomics by developing five groundbreaking instruments - the protein sequencer (1982), the DNA synthesizer (1983), the peptide synthesizer (1984),the automated DNA sequencer (1986) and later the ink-jet DNA synthesizer. Hood's instruments incorporated concepts of high throughput data accumulation through automation and parallelization. When applied to the study of protein and DNA chemistries, these ideas were essential to the rapid deciphering of biological information. Hood had a strong interest in commercial development, actively filing patents and seeking private funding. Applied Biosystems, Inc. (initially named GeneCo.) was formed in 1981 in Foster City, California, to commercialize instruments developed by Hood, Hunkapiller, Caruthers, and others. The company was supported by venture capitalist William K. Bowes, who hired Sam H. Eletr and André Marion as president and vice-president of the new company. The company shipped the first gas phase protein sequencer, Model 4790A, in August 1982. The 380 DNA synthesizer was commercialized in 1983, the 430A peptide synthesizer in 1984, and the 370A DNA sequencing system in 1986. These new instruments had a major impact on the emerging fields of proteomics and genomics. The gas-liquid phase protein sequencer was developed with Michael W. Hunkapiller, then a research fellow at Caltech. The instrument makes use of the chemical process known as the Edman degradation, devised by Pehr Edman.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.